ROIV - Roivant slides on failed Phase 2 study for lupus drug candidate
2023-11-27 11:19:40 ET
More on Roivant Sciences
- Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
- Roivant Sciences Ltd. 2023 Q2 - Results - Earnings Call Presentation
- Roivant Sciences: Risk-Transforming Deal Met With Crickets
- Biggest stock movers today: Foot Locker, Shopify, UP Fintech and more
- Roivant Sciences Q2 2024 Earnings Preview
For further details see:
Roivant slides on failed Phase 2 study for lupus drug candidate